Form 4: Singular Genomics Systems Director, Jason Ryan, Acquires 74,000 Stock Options
SEC Form 4 Filing
Jason Ryan, a director at Singular Genomics Systems, acquired 74,000 stock options on May 29, 2024, exercisable at $0.372 per share.
Summary
- Jason Ryan, a director of Singular Genomics Systems, Inc. [OMIC], reported a transaction on May 29, 2024.
- Ryan acquired 74,000 stock options with an exercise price of $0.372.
- These options vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025.
- The options expire on May 29, 2034.
- Following the transaction, Ryan directly owns 74,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and officers.
Stakeholder Impact
- The transaction could be of interest to shareholders as it provides insight into the director's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of earliest transaction: acquisition of stock options. |
| 05/29/2024 | Date of stock option grant. |
| 05/29/2025 | Options vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or this date. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.